As the year draws to a close, we take a look at some of the biggest science stories of the year, and why they matter.

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

Prime Medicine Inc. (NASDAQ: PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

In one of the rockiest years yet for science, Philadelphia-area researchers still managed to celebrate many wins. Here are five of them.

For all of the political chaos that American science endured in 2025, aspects of this country’s research enterprise made it ...

Two genetic innovations could address major welfare and productivity issues within the broiler and layer industries.

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

By one calculation, spending on AI accounted for 92 percent of America’s GDP growth in the first half of 2025. This year, a ...